Processa Pharmaceuticals R&D President Buys 1,810 PCSA Shares; Company Reports Phase 2 Dosing Complete
David Young, President of Research & Development at Processa Pharmaceuticals, purchased 1,810 shares of the company on March 31, 2026, for $2.535 per share, a $4,588 transaction. Following the purchase Young's direct holding rose to 10,562 shares, with additional indirect holdings across a trust, family entities, and an LLC. Processa, a small-cap b…